Drugs

, Volume 70, Issue 2, pp 147–165 | Cite as

Pegylated Interferons for the Treatment of Chronic Hepatitis C

Pharmacological and Clinical Differences between Peginterferon-α-2a and Peginterferon-α-2b
Review Article

Abstract

Chronic infection with hepatitis C virus (HCV) is a major healthcare problem, affecting an estimated 170 million people worldwide. Interferon-α has formed the basis of treatment regimens since the identification of HCV, either alone or in conjunction with the nucleoside analogue ribavirin. The relatively recent introduction of pegylated forms of interferon-α, with greater stability and in vivo activity, has substantially improved sustained virological response (SVR) rates compared with unmodified interferon-α, with SVR rates of 35–66% when used in conjunction with ribavirin in randomized controlled trials.

Two pegylated interferon (peginterferon)-α molecules are commercially available for the treatment of chronic hepatitis C, and these differ in the size and nature of the covalently attached polyethylene glycol (PEG) moiety, with resulting differences in pharmacokinetics and in dosing regimens. Peg-interferon-α-2b has a linear 12 kDa PEG chain covalently attached primarily to histidine-34 of interferon-α-2b via an unstable urethane bond that is subject to hydrolysis once injected, releasing native interferon-α-2b. The branched, 40 kDa PEG chain of peginterferon-α-2a is covalently attached via stable amide bonds to lysine residues of interferon-α-2a, and circulates as an intact molecule. Consequently, peginterferon-α-2a has a very restricted volume of distribution, longer half-life and reduced clearance compared with native interferon-α-2a, and can be given once weekly independently of bodyweight. Peginterferon-α-2b has a shorter half-life in serum than peginterferon-α-2a and requires bodyweight-based dosing.

The majority of head-to-head randomized controlled trials, including the large, randomized IDEAL (Individualized Dosing Efficacy versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy) trial (n = 3070), demonstrated similar SVR rates for peginterferon-α-2a and peginterferon-α-2b (41% vs 39% in IDEAL), in combination with ribavirin; however, two randomized controlled trials (n = 431 and 320) demonstrated a statistically significant benefit for peginterferon-α-2a (66% vs 54%, and 69% vs 54%). Furthermore, two large retrospective studies and one prospective observational study in real-life settings have shown a significant benefit for peginter-feron-α-2a versus peginterferon-α-2b, although SVR rates were generally lower than those seen in controlled trials.

The use of interferon-α with or without ribavirin is frequently associated with a range of adverse effects, including influenza-like symptoms, haematological changes and neuropsychiatric disturbances, and this is true also of the peginterferons, with similar levels of adverse events, dose reduction and discontinuation from treatment. Peginterferon-α-2a and peginterferon-α-2b appear from comparative studies to be similarly tolerated, with few differences of clinical significance noted. Peginterferon plus ribavirin, as the standard of care for patients with chronic hepatitis C, may in the future form the basis of improved treatment regimens that include new, targeted anti-HCV agents to increase SVR rates even further.

References

  1. 1.
    World Health Organization. Hepatitis C, 2004 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs164/en/index.html [Accessed 2009 Apr 7]
  2. 2.
    Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 Apr; 39(4): 1147–71PubMedCrossRefGoogle Scholar
  3. 3.
    Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 Oct; 45(4): 529–38PubMedCrossRefGoogle Scholar
  4. 4.
    Lee CM, Hung CH, Lu SN, et al. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. Chang Gung Med J 2008 Jan–Feb; 31(1): 16–25PubMedGoogle Scholar
  5. 5.
    Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007 Jul; 42(7): 513–21PubMedCrossRefGoogle Scholar
  6. 6.
    NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002 Jun 10–12; 19 (3): 1–46Google Scholar
  7. 7.
    Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005 Oct; 3 (10 Suppl. 2): S97–101PubMedCrossRefGoogle Scholar
  8. 8.
    Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther 2008; 13 Suppl. 1: 3–8PubMedGoogle Scholar
  9. 9.
    Foster GR. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004 Oct 15; 20(8): 825–30PubMedCrossRefGoogle Scholar
  10. 10.
    Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006 Feb; 44(2): 275–82PubMedCrossRefGoogle Scholar
  11. 11.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26; 347(13): 975–82PubMedCrossRefGoogle Scholar
  12. 12.
    Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterfer-on-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 Mar 2; 140(5): 346–55PubMedGoogle Scholar
  13. 13.
    Jacobson IM, Brown Jr RS, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007 Oct; 46(4): 971–81PubMedCrossRefGoogle Scholar
  14. 14.
    Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 Jun 23; 352(25): 2609–17PubMedCrossRefGoogle Scholar
  15. 15.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 Sep 22; 358(9286): 958–65PubMedCrossRefGoogle Scholar
  16. 16.
    Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 Jun; 40(6): 993–9PubMedCrossRefGoogle Scholar
  17. 17.
    Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002; 62(3): 507–56PubMedCrossRefGoogle Scholar
  18. 18.
    Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003; 63(7): 701–30PubMedCrossRefGoogle Scholar
  19. 19.
    Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61(15): 2263–88PubMedCrossRefGoogle Scholar
  20. 20.
    Palumbo E. PEG-interferon alpha-2b for acute hepatitis C: a review. Mini Rev Med Chem 2007 Aug; 7(8): 839–43PubMedCrossRefGoogle Scholar
  21. 21.
    Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000 Nov; 68(5): 556–67Google Scholar
  22. 22.
    Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009 Jan; 6(1): 1–16PubMedCrossRefGoogle Scholar
  23. 23.
    Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008; 22(5): 315–29PubMedCrossRefGoogle Scholar
  24. 24.
    Youngster S, Wang YS, Grace M, et al. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002; 8(24): 2139–57PubMedCrossRefGoogle Scholar
  25. 25.
    Schering-Plough Corporation. Peglntron® (peginterferon alfa-2b): full prescribing information [online]. Available from URL: http://www.pegintron.com/peg/application/websites/pegintron-com.aspx [Accessed 2009 Dec 8]
  26. 26.
    Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001 Mar–Apr; 12(2): 195–202PubMedCrossRefGoogle Scholar
  27. 27.
    Roche Laboratories Inc. Pegasys® (peginterferon alfa-2a): complete product information [online]. Available from URL: http://www.rocheusa.com/products/pegasys/pi.pdf [Accessed 2009 Dec 8]
  28. 28.
    Baron S, Tyring SK, Fleischmann Jr WR, et al. The interferons. mechanisms of action and clinical applications.JAMA 1991 Sep 11; 266(10): 1375–83PubMedCrossRefGoogle Scholar
  29. 29.
    Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255–81PubMedCrossRefGoogle Scholar
  30. 30.
    Dhalluin C, Ross A, Huber W, et al. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem 2005 May–Jun; 16(3): 518–27PubMedCrossRefGoogle Scholar
  31. 31.
    Foser S, Schacher A, Weyer KA, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 2003 Jul; 30(1): 78–87PubMedCrossRefGoogle Scholar
  32. 32.
    Shindo M, Hamada K, Morikawa T, et al. In vivo interferon system assessed by 2′-5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin. Hepatol Res 2008 Dec; 38(12): 1213–20PubMedGoogle Scholar
  33. 33.
    Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007 Aug 1; 26(3): 369–76PubMedCrossRefGoogle Scholar
  34. 34.
    Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006 Aug; 45(2): 204–13PubMedCrossRefGoogle Scholar
  35. 35.
    Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginter-feron alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004 Aug; 9(4): 491–7PubMedGoogle Scholar
  36. 36.
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007 Oct; 14(10): 721–9PubMedGoogle Scholar
  37. 37.
    Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003 Jul; 10(4): 271–6PubMedCrossRefGoogle Scholar
  38. 38.
    Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004 Oct; 8(39): iii–iv, 1–125PubMedGoogle Scholar
  39. 39.
    Zaman A, Fennerty MB, Keeffe EB. Systematic review: peginterferon versus standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003 Oct 1; 18(7): 661–70PubMedCrossRefGoogle Scholar
  40. 40.
    Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 Apr; 49(4): 1335–74PubMedCrossRefGoogle Scholar
  41. 41.
    Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl. 1: 9–16PubMedGoogle Scholar
  42. 42.
    Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008 Jan 1; 46(1): 78–84PubMedCrossRefGoogle Scholar
  43. 43.
    Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009 Feb; 16(2): 75–90PubMedCrossRefGoogle Scholar
  44. 44.
    Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 Dec; 40(6): 1260–5PubMedCrossRefGoogle Scholar
  45. 45.
    Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 May; 43(5): 954–60PubMedCrossRefGoogle Scholar
  46. 46.
    Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 Jul 12; 357(2): 124–34PubMedCrossRefGoogle Scholar
  47. 47.
    von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastro-enterology 2005 Aug; 129(2): 522–7CrossRefGoogle Scholar
  48. 48.
    Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 Apr; 56(4): 553–9PubMedCrossRefGoogle Scholar
  49. 49.
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 Jul 22; 361: 580–93PubMedCrossRefGoogle Scholar
  50. 50.
    Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008 Jan; 47(1): 43–50PubMedCrossRefGoogle Scholar
  51. 51.
    Sporea I, Danila M, Sirli R, et al. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointestin Liver Dis 2006 Jun; 15(2): 125–30PubMedGoogle Scholar
  52. 52.
    Escudero A, Rodriguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated al-pha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol 2008 Jun; 23(6): 861–6PubMedCrossRefGoogle Scholar
  53. 53.
    Scotto G, Fazio V, Fornabaio C, et al. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs 2008; 68(6): 791–801PubMedCrossRefGoogle Scholar
  54. 54.
    Scotto G, Fazio V, Fornabaio C, et al. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008 Oct; 28(10): 623–9PubMedCrossRefGoogle Scholar
  55. 55.
    Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009 Jan; 49(1): 22–31PubMedCrossRefGoogle Scholar
  56. 56.
    Vispo E, Barreiro P, Rodriguez-Novoa S, et al. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antivir Ther 2008; 13(4): 511–7PubMedGoogle Scholar
  57. 57.
    Silva MO. Compare trial: updated data. J Hepatol 2008 Aug; 49(2): 288–9PubMedCrossRefGoogle Scholar
  58. 58.
    Soriano V, Barreiro P, Martin-Carbonero L, et al. Update on the treatment of chronic hepatitis C in HIV-infected patients. AIDS Rev 2007 Apr–Jun; 9(2): 99–113PubMedGoogle Scholar
  59. 59.
    Roberts SK, Weltman MD, Crawford DH, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009 Oct; 50(4): 1045–55PubMedCrossRefGoogle Scholar
  60. 60.
    McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008 Jul; 15(7): 475–81PubMedCrossRefGoogle Scholar
  61. 61.
    Rumi M, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alfa2a plus ribavirin versus peginterferon-alfa2b plus ribavirin in chronic hepatitis C. Gastroenterology. Epub 2009 Sep 17: doi: 10.1053/j.gastro0.2009. 08.071Google Scholar
  62. 62.
    Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J Hepatol 2008; 48 Suppl. 2: S370CrossRefGoogle Scholar
  63. 63.
    Berak H, Kolakowska-Rzadzka A, Wasilewski M, et al. Comparison of efficacy of treatment with peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin among patients chronically infected with non 2/3 HCV genotypes with low and high pretreatment viral load. Hepatology 2007; 46 Suppl. 1: 385A–6AGoogle Scholar
  64. 64.
    Yenice N, Mehtap O, Gumrah M, et al. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006 Jun; 17(2): 94–8PubMedGoogle Scholar
  65. 65.
    Craxi A, Piccinino F, Alberti A, et al. Predictors of SVR in naive HCV G1 patients in real life practice: the PROBE [abstract]. J Hepatol 2008; 48 Suppl. 2: S291CrossRefGoogle Scholar
  66. 66.
    Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007 Jul; 46(1): 37–47PubMedCrossRefGoogle Scholar
  67. 67.
    Witthoeft T, Hueppe D, John C, et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the PRACTICE study. J Hepatol 2008; 48 Suppl. 2: S315CrossRefGoogle Scholar
  68. 68.
    Thuy PT, Dat HT. Comparison between the two peginterferons alfa in the treatment of chronic hepatitis C. Hepatol 2007; 46 (4 Suppl. 1): 387A–8ACrossRefGoogle Scholar
  69. 69.
    Mauss S, Berger F, Schmutz G. Peginterferon alfa-2a versus peginterferon alfa-2b in the treatment of chronic hepatitis C. Hepatology 2004; 46 Suppl. 4: 730AGoogle Scholar
  70. 70.
    Vispo E, Tuma P, Medrano J, et al. Differences in antiviral activity and tolerability between pegylated interferon alpha-2a and -2b in HIV infected patients with chronic hepatitis C. J Hepatol 2009; 50 Suppl. 1: S238–S9CrossRefGoogle Scholar
  71. 71.
    Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008 Oct; 48(4): 1033–43PubMedCrossRefGoogle Scholar
  72. 72.
    Zopf S, Herold C, Hahn EG, et al. Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation. Scand J Gastroenterol 2009; 44(4): 486–90PubMedCrossRefGoogle Scholar
  73. 73.
    Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 Jan; 5(1): 124–9PubMedCrossRefGoogle Scholar
  74. 74.
    Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008 Jun; 47(6): 1884–93PubMedCrossRefGoogle Scholar
  75. 75.
    Hammoud I, Sherbondy MH, Moonka D, et al. Peginterferon alpha-2b versus peginterferon alpha-2a in the treatment of chronic hepatitis C infection. Hepatology 2007; 46 Suppl. 1: 386A–7AGoogle Scholar
  76. 76.
    Kolakowska-Rzadzka A, Berak H, Wasilewski M, et al. Relevance between fibrosis and response to treatment with peginterferon alfa2a versus alfa2b with ribavirin in chronic hepatitis C genotype 3 patients: randomized open label study. Hepatology 2008; 48 Suppl. 1: 878AGoogle Scholar
  77. 77.
    Marquez-Peiro JF, Valero-Alcocer VE, Morales-Suarez-Varela MM, et al. Effectiveness of peginterferon alpha-2a or -2b plus ribavirin in naive patients with hepatitis C infection. Enferm Infec Microbiol Clin 2008 Mar; 26(3): 135–40CrossRefGoogle Scholar
  78. 78.
    Rizzetto M, Colombo M, Ascione A, et al. Effectiveness of hepatitis C virus treatment in real-life practice: a prospective observational multicenter study in Italy (PROBE). J Hepatol 2008; 48 Suppl. 2: S311CrossRefGoogle Scholar
  79. 79.
    Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009 Apr 21; 150(8): 528–40PubMedGoogle Scholar
  80. 80.
    Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009 May; 136(5): 1618–28 e2PubMedCrossRefGoogle Scholar
  81. 81.
    Rustgi VK, Esposito S, Hamzeh FM, et al. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2008 Mar 1; 27(5): 433–40PubMedCrossRefGoogle Scholar
  82. 82.
    Kaiser S, Lutze B, Hass HG, et al. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2a (40Kd) plus ribavirin for 72 weeks. Hepatol 2008; 48 Suppl. 1: 1140AGoogle Scholar
  83. 83.
    Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003 Feb 4; 138(3): 197–207PubMedGoogle Scholar
  84. 84.
    Plosker GL, Keating GM. Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in hepatitis C virus and HIV co-infection. Drugs 2004; 64(24): 2823–43PubMedCrossRefGoogle Scholar
  85. 85.
    Zhao S, Cheng D, Liu E, et al. Peginterferon versus interferon in the treatment of different HCV genotype infections in HIV patients. Eur J Clin Microbiol Infect Dis 2008 Dec; 27(12): 1183–92PubMedCrossRefGoogle Scholar
  86. 86.
    Crespo M, Mira JA, Pineda JA, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother 2008 Oct; 62(4): 793–6PubMedCrossRefGoogle Scholar
  87. 87.
    Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon (alpha)2a plus ribavirin versus pegylated interferon (alpha)2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009 Jun; 63(6): 1256–63PubMedCrossRefGoogle Scholar
  88. 88.
    Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007 Mar; 45(3): 806–16PubMedCrossRefGoogle Scholar
  89. 89.
    Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21(5): 341–9PubMedCrossRefGoogle Scholar
  90. 90.
    Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004 Apr; 40(4): 675–81PubMedCrossRefGoogle Scholar
  91. 91.
    Nayman Alpat S, Usluer G, Yavuz H, et al. Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life. J Chemother 2008 Feb; 20(1): 101–5PubMedGoogle Scholar
  92. 92.
    Hashemi N, Rossi S, Navarro VJ, et al. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf 2008 Nov; 7(6): 771–81PubMedCrossRefGoogle Scholar
  93. 93.
    Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 Nov; 36 (5 Suppl. 1): S237–44PubMedCrossRefGoogle Scholar
  94. 94.
    Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006; 26(11): 655–62PubMedCrossRefGoogle Scholar
  95. 95.
    Puoti M, Babudieri S, Rezza G, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004 Aug; 9(4): 627–30PubMedGoogle Scholar
  96. 96.
    Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008 Jun; 36(3): 250–5PubMedCrossRefGoogle Scholar
  97. 97.
    Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med 2009 Apr 30; 360(18): 1899–901PubMedCrossRefGoogle Scholar
  98. 98.
    Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 Apr 30; 360(18): 1839–50PubMedCrossRefGoogle Scholar
  99. 99.
    McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009 Apr 30; 360(18): 1827–38PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.The Liver Unit, Blizard Institute of Cellular and Molecular Science, Barts and The London School of Medicine, The Royal London HospitalQueen Mary University of LondonLondonUK

Personalised recommendations